Nurullah Akkoc1, Muhammad A Khan2. 1. Division of Rheumatology, Department of Medicine, Manisa Celal Bayar University School of Medicine, Manisa, Turkey. nurullah.akkoc@gmail.com. 2. School of Medicine, Case Western Reserve University, 1722 Coes Post Run, Westlake, OH, 44145, USA.
Abstract
PURPOSE OF REVIEW: To discuss the potential role of JAK inhibitors (JAKis) as a new therapeutic class for the treatment of axial spondyloarthritis (axSpA, including ankylosing spondylitis [AS] and non-radiographic axSpA [nr-axSpA]). RECENT FINDINGS: A phase III randomized controlled trial of tofacitinib (a "pan JAKi") in patients with active AS was found to be superior to placebo in achieving the ASAS20 primary endpoint at week 16 (56.4% and 29.4%, p < 0.0001, phase II trials of AS). Upadacitinib, a JAK1 inhibitor, has also been evaluated in a phase III trial for its efficacy and safety in AS. The primary endpoint, ASAS40 at week 16, was reached by 52% of the patients randomized to upadacitinib and 26% of the patients receiving placebo (p = 0·0003). All the important secondary endpoints also improved with both agents. No new changes in their safety profile were noted. However, the more frequent occurrence of cardiovascular and cancer adverse events associated with tofacitinib than with TNFi observed in the very recent post-marketing "ORAL surveillance" safety study, the results of which were released on January 27, 2021, may lead to safety concerns swirling around the whole class of JAKis. JAKis seem to be effective in treating signs and symptoms of AS but have not been studied in nr-axSpA. Both tofacitinib and upadacitinib have been pre-registered with the FDA for the treatment of AS. Upadacitinib has just recently received approval for this indication in the European Union..
RCT Entities:
PURPOSE OF REVIEW: To discuss the potential role of JAK inhibitors (JAKis) as a new therapeutic class for the treatment of axial spondyloarthritis (axSpA, including ankylosing spondylitis [AS] and non-radiographic axSpA [nr-axSpA]). RECENT FINDINGS: A phase III randomized controlled trial of tofacitinib (a "pan JAKi") in patients with active AS was found to be superior to placebo in achieving the ASAS20 primary endpoint at week 16 (56.4% and 29.4%, p < 0.0001, phase II trials of AS). Upadacitinib, a JAK1 inhibitor, has also been evaluated in a phase III trial for its efficacy and safety in AS. The primary endpoint, ASAS40 at week 16, was reached by 52% of the patients randomized to upadacitinib and 26% of the patients receiving placebo (p = 0·0003). All the important secondary endpoints also improved with both agents. No new changes in their safety profile were noted. However, the more frequent occurrence of cardiovascular and cancer adverse events associated with tofacitinib than with TNFi observed in the very recent post-marketing "ORAL surveillance" safety study, the results of which were released on January 27, 2021, may lead to safety concerns swirling around the whole class of JAKis. JAKis seem to be effective in treating signs and symptoms of AS but have not been studied in nr-axSpA. Both tofacitinib and upadacitinib have been pre-registered with the FDA for the treatment of AS. Upadacitinib has just recently received approval for this indication in the European Union..
Entities:
Keywords:
Ankylosing spondylitis; Axial spondyloarthritis; Filgotinib; JAK inhibitors; Tofacitinib; Upadacitinib
Authors: José María G Ruiz de Morales; Lluís Puig; Esteban Daudén; Juan D Cañete; José Luis Pablos; Antonio Olveira Martín; Carlos González Juanatey; Alfredo Adán; Xavier Montalbán; Natalia Borruel; Guillermo Ortí; Esther Holgado-Martín; Carolina García-Vidal; Cynthia Vizcaya-Morales; Víctor Martín-Vázquez; Miguel Ángel González-Gay Journal: Autoimmun Rev Date: 2019-11-15 Impact factor: 9.754
Authors: Atul Deodhar; Lianne S Gensler; Joachim Sieper; Michael Clark; Cesar Calderon; Yuhua Wang; Yiying Zhou; Jocelyn H Leu; Kim Campbell; Kristen Sweet; Diane D Harrison; Elizabeth C Hsia; Désirée van der Heijde Journal: Arthritis Rheumatol Date: 2018-12-29 Impact factor: 10.995
Authors: Dominique Baeten; Mikkel Østergaard; James Cheng-Chung Wei; Joachim Sieper; Pentti Järvinen; Lai-Shan Tam; Carlo Salvarani; Tae-Hwan Kim; Alan Solinger; Yakov Datsenko; Chandrasena Pamulapati; Sudha Visvanathan; David B Hall; Stella Aslanyan; Paul Scholl; Steven J Padula Journal: Ann Rheum Dis Date: 2018-06-26 Impact factor: 19.103
Authors: Ernest H Choy; Fabrizio De Benedetti; Tsutomu Takeuchi; Misato Hashizume; Markus R John; Tadamitsu Kishimoto Journal: Nat Rev Rheumatol Date: 2020-04-23 Impact factor: 20.543
Authors: Joachim Sieper; Jürgen Braun; Jonathan Kay; Salvatore Badalamenti; Allen R Radin; Lixia Jiao; Stefano Fiore; Tanya Momtahen; George D Yancopoulos; Neil Stahl; Robert D Inman Journal: Ann Rheum Dis Date: 2014-02-18 Impact factor: 19.103
Authors: Joachim Sieper; Benjamin Porter-Brown; Liz Thompson; Olivier Harari; Maxime Dougados Journal: Ann Rheum Dis Date: 2013-06-13 Impact factor: 19.103
Authors: Désirée van der Heijde; Atul Deodhar; Walter P Maksymowych; Joachim Sieper; Filip Van den Bosch; Tae-Hwan Kim; Mitsumasa Kishimoto; Andrew J Östör; Bernard Combe; Yunxia Sui; Yuanyuan Duan; Peter K Wung; In-Ho Song Journal: RMD Open Date: 2022-07
Authors: Atul Deodhar; Désirée van der Heijde; Joachim Sieper; Filip Van den Bosch; Walter P Maksymowych; Tae-Hwan Kim; Mitsumasa Kishimoto; Andrew Ostor; Bernard Combe; Yunxia Sui; Alvina D Chu; In-Ho Song Journal: Arthritis Rheumatol Date: 2021-11-12 Impact factor: 15.483